Study guide
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology
CBCN Certified Breast Care Nurse Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CBCN Exam
CBCN Exam Facts, 2026 Blueprint & Study Plan
2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)
1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes
3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)
2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations
4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation
5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance
6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)
5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques
7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification
8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)
7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET
9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery
10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)
9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens
11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)
10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)
11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations
13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)
12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy
14 Chapter 13: Oncologic Emergencies (Nursing Practice)
13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)
14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use
16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)
15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology
Key Takeaways Explain This Topic AI
The Dupont and Page classification stratifies benign breast conditions into three evidence-based tiers: non-proliferative (no increased risk, RR ~1.0), proliferative without atypia (slight risk, RR 1.5–2.0), and proliferative with atypia (moderate-to-high risk, RR 4.0–5.0).
Proliferative lesions without atypia include complex fibroadenomas, intraductal papillomas, sclerosing adenosis, and radial scars; radial scars require multidisciplinary review and frequent excision due to their histological mimicry of tubular carcinoma and biopsy upgrade potential.
Atypical ductal hyperplasia (ADH) shares cytologic features with low-grade DCIS but has limited extent (under 2 mm or fewer than two complete duct spaces); core needle biopsy carries an upgrade rate of 10% to 30% to DCIS or invasive cancer, establishing surgical excision as the standard of care.
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) are characterized by discohesive cells with loss of E-cadherin expression; unlike classic LCIS which serves as a bilateral risk marker, pleomorphic LCIS (PLCIS) behaves like a direct precursor lesion and is excised to negative margins, much like DCIS.
High-risk benign lesions with atypia confer a 25-year cumulative breast cancer risk of 25% to 30% in both breasts, warranting annual mammography (with MRI considered when the calculated lifetime risk is 20% or higher) and discussion of risk-reducing endocrine therapy (tamoxifen, raloxifene, or an aromatase inhibitor).
Last updated: September 2026
The Dupont and Page Pathological Classification
Historically, all benign breast conditions were grouped under ambiguous clinical terms such as "fibrocystic disease." In landmark longitudinal cohort studies initiated at Vanderbilt University, biostatistician William Dupont and pathologist David Page revolutionized breast oncology by demonstrating that benign breast lesions represent a distinct histological continuum directly correlating with future invasive breast cancer risk.
The Three Diagnostic Tiers
The Dupont and Page classification stratifies all benign breast pathologies into three objective, reproducible tiers based on relative risk (RR) compared to age-matched women in the general population:
Non-Proliferative Lesions (Relative Risk: ~1.0; No Increased Risk) :
Histological entities : Simple cysts, apocrine metaplasia (without atypia), duct ectasia, mild ductal hyperplasia of usual type (defined as epithelial lining 2 to 4 cells thick without bridging), periductal fibrosis, galactoceles, and fat necrosis.
Clinical significance : These lesions do not confer any meaningful increase in future breast cancer risk. Management is guided purely by symptomatic relief and reassurance.
Proliferative Lesions Without Atypia (Relative Risk: 1.5 to 2.0; Slight Increase in Risk) :
Histological entities : Moderate or florid ductal hyperplasia of usual type (UDH), complex fibroadenomas, solitary and multiple intraductal papillomas, sclerosing adenosis, and radial scars / complex sclerosing lesions.
Clinical significance : Women diagnosed with these lesions face a slightly elevated relative risk (1.5-fold to 2.0-fold). Absolute lifetime breast cancer risk remains modest (~10% to 15%), and routine aggressive chemoprevention is generally not indicated.
Proliferative Lesions With Atypia (Atypical Hyperplasia) (Relative Risk: 4.0 to 5.0; Substantial Elevation in Risk) :
Histological entities : Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH).
Clinical significance : Represents a powerful independent clinical risk factor. The relative risk of subsequent invasive breast cancer is 4-fold to 5-fold higher than baseline. When atypical hyperplasia is identified in a woman with a positive family history of breast cancer in a first-degree relative, the relative risk increases to 9.0 to 11.0 .
Absolute Long-Term Cumulative Cancer Risk
While relative risk estimates are useful in epidemiology, clinical communication requires understanding absolute cumulative risk. Longitudinal data from the Mayo Clinic Benign Breast Disease Cohort (Hartmann et al.) established that women diagnosed with atypical hyperplasia experience a continuous, linear risk accumulation over decades:
At 10 years post-biopsy: Cumulative breast cancer incidence is approximately 7% to 10% .
At 25 years post-biopsy: Cumulative breast cancer incidence reaches 25% to 30% .
This represents an absolute cancer excess rate of roughly 1% per year following diagnosis, which is why atypical hyperplasia prompts formal risk modeling, discussion of risk-reducing medication, and consideration of supplemental MRI when the calculated lifetime risk reaches 20% or higher. Dupont & Page Classification:
- ┌───────────────────────────────────────┬──────────────┬─────────────────────────┐
- │ Histological Tier │ Relative │ 25-Year Cumulative │
- │ │ Risk (RR) │ Breast Cancer Risk │
- ├───────────────────────────────────────┼──────────────┼─────────────────────────┤
- │ 1. Non-Proliferative │ ~1.0 (None) │ ~5% (General baseline) │
- │ 2. Proliferative Without Atypia │ 1.5 - 2.0 │ ~10% - 15% │
- │ 3. Proliferative With Atypia (ADH/ALH)│ 4.0 - 5.0 │ 25% - 30% (High risk) │
- └───────────────────────────────────────┴──────────────┴─────────────────────────┘